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meeting report

Promise and complexity of lupus mouse models
As a follow up to a 2010 meeting deliberating on the benefits of studying mouse models of systemic lupus
erythematosus (SLE), the virtual conference “Mouse models of lupus 10 years later” convened on 10 December
2020 to address a challenging decade that saw few new therapies approved, despite leaps in knowledge.
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bnormalities in both innate and
adaptive immunity characterize
SLE, a systemic autoimmune disease
with potentially severe consequences in
patients. Treatment has traditionally been
limited to broad-acting, side-effect-heavy
immunosuppressants, which are also
incompletely effective. Thus, the need for
specific therapies targeting the pathogenic
mechanisms of SLE remains unmet.
Affirming the utility of mouse models in
lupus research, a meeting convened in
2010 recommended that the next decade’s
research embrace these for their mechanistic
insights; their diversity of phenotypes,
which mirrors the heterogeneity observed
among patients with lupus; and as a platform
for clinical exploration. A decade later,
hope persists; studies of murine models of
lupus have uncovered putative therapies,
and many were moved to clinical trials.
Unfortunately, few interventions improved
patient outcomes: belimumab was the sole
therapy brought to market in the 2010s.
The continuing difficulties in translating
potential into success1–3 prompted a second
conference, which was recorded.
On 10 December 2020, leading scientists
and clinicians from all over the world, in
partnership with the National Institutes of
Health and the National Cancer Institute,
gathered virtually. Hans-Joachim Anders
(Ludwig Maximilian University of Munich)
sparked much discussion with his opening
address highlighting the multiple clinical
trial design, diagnostic and scientific pitfalls
that have seriously hindered translating
success in lupus models to humans. Four
scientific sessions followed, each delving
into recent basic and translational advances
in our understanding and treatment of SLE.
In his closing keynote talk, Eric Morand
(Monash University) proposed that the
recent study of the interferon signature in
SLE and the interventions it produced be
used as a model for moving between human
studies and mouse models, while stressing
the scientific considerations needed to
successfully utilize lupus models. Through
discussions during the 2020 conference,
participants aimed to revisit the utility of
mouse models in the study of lupus by
answering the following questions: Have
animal models expanded our understanding
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Fig. 1 | Dysbiosis and gut permeability contribute to lupus disease. Expansion of pathogenic gut
microbiota can lead to increased permeability of the gut epithelial barrier, providing a route through which
bacteria and bacterial antigens can enter systemic circulation. The immune response to these foreign
epitopes may generate self-reactive antibodies, such as anti-curli–DNA, and contribute to lupus pathology.

of lupus pathogenesis? In what ways can we
target the mediators of the lupus immune
response? How has advanced technology
been merged with the study of both lupus
models and patients with lupus?

Infection and microbiome

Extraneous infection and the resident
microbiome both act as routes through
which a predisposed immune system may
be hyperstimulated to precipitate loss of
tolerance and trigger autoimmunity (Fig. 1).
Mark Shlomchik (University of Pittsburgh)
reported that experimental autoimmunity
following Salmonella infection results from
marked extrafollicular expansion of B cell
populations, and the rapid maturation of
B cells outside germinal centers increases
autoantibody levels4. Interleukin (IL)-12
mediates this extrafollicular-dominant
autoimmune “storm” by suppressing
follicular helper T (TFH) cells necessary for
germinal center formation5, suggesting that
IL-12 inhibition could treat patients with
lupus who have similar immune responses.
Stefania Gallucci and Çağla Tükel (Temple
University) introduced a specific microbial
driver of autoantibody production. The
amyloid–nucleic acid compound curli–DNA,
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an Enterobacteriaceae biofilm component, is
found throughout the murine intestinal tract
during Salmonella infection. Tükel provided
evidence that curli–DNA may trigger
autoimmunity once it enters the blood via
the intestinal epithelia or when it is shed by
biofilm-bearing catheters6. Gallucci’s group
supported this hypothesis, showing that
intraperitoneal injection of curli–DNA in
lupus NZB×W/F1 mice increased circulating
autoantibody and type I interferon (IFN)
concentrations and activated macrophages
and dendritic cells7. In addition to these
hallmarks of SLE, curli–DNA appeared to
induce B cell class switching independently
of T cells. Finally, Gallucci described
circulating anti-curli–DNA antibodies whose
levels correlate with flares of active disease in
patients with lupus8.
Supporting the hypothesis of a defective
intestinal barrier exposing the immune
system to microbiota and their products,
Gregg Silverman (New York University)
presented analyses of stool samples from
patients with SLE that showed evidence
of a more permeable gut. Additionally, his
group characterized a new dysbiosis in
patients with SLE, with skewing toward
more Ruminococcus gnavus bacteria and

U.S. government works are not subject to copyright.

683

meeting report

Systemic lupus
erythematosus

Brain

Skin

Healthy
control

Kidney

Fig. 2 | The potential application of T cell phenotyping and TCR sequence monitoring at both the organ
and disease levels. T cells play a key role in organ damage caused by lupus disease. Sequencing of a
T cell receptor could potentially reveal its cognate antigen, including autoantigens. TCRs can be disease
and organ specific, so monitoring a patient’s TCR repertoire could not only enable a lupus diagnosis but
could also reveal organs potentially involved in the patient’s disease.

fewer protective species. Serology from
these patients showed antibodies that react
to a bacterial cell wall lipoglycan, which
correlated with active renal disease9. With
this knowledge, Silverman’s group colonized
germ-free C57BL/6 mice with R. gnavus
bacteria and saw levels of serum R. gnavus
DNA rise, accompanied by elevations in gut
permeability and zonulin. Administration
of larazotide, a tight-junction regulator,
reduced gut permeability, suggesting that R.
gnavus induces elevated zonulin and disrupts
tight junctions to increase gut permeability.
Similarly, Martin Kriegel (Yale University)
presented evidence from both mice and
human studies that Enterococcus gallinarum
induces a more permeable gut, enabling its
transmigration to the liver and lymph nodes.
Significant immune activation, including
rising type I IFN levels and anti-E. gallinarum
antibodies, accompanies this process10.
Interestingly, Kriegel’s group developed a
vaccine that is able to suppress transmigration
of E. gallinarum, which could be a new
treatment strategy for autoimmunity related
to microbiome dysbiosis.
Xin Luo (Virginia Tech University)
characterized the microbiome of diseased
MRL/lpr mice; more Lachnospiraceae
and fewer Lactobacillaceae were found11,
representing another pathogenic dysbiosis.
The putatively protective Lactobacillaceae
were then gavage delivered to female MRL/lpr
mice, resulting in improved systemic and
renal disease later in life12. Oral administration
of vancomycin lessened or worsened lupus
684

whether given before or after disease onset,
respectively, suggesting different mechanistic
effects on the immune system13.
Daniel Zegarra-Ruiz (Memorial Sloan
Kettering Cancer Center) presented
additional findings that point to diet as a
contributing factor in murine dysbiosis and
lupus. High fiber content in the diets of
Toll-like receptor 7–transgenic mice resolved
the dysbiosis that contributed to increased
gut permeability and a lupus phenotype14.
The roles of infection, the microbiome,
gut permeability and systemic bacterial
products in lupus pathogenesis are only
just being appreciated; nevertheless, strong
evidence points to robust and far-reaching
effects of dysbiosis in mice and humans who
are predisposed. While it is impractical to
sterilize and then specifically reconstitute
the human microbiome, researchers may
longitudinally characterize and manipulate
a simulated human microbiome in mice
as well as evaluate its relationship with
disease onset. Mouse models, therefore,
are fundamental to advancing our
understanding of the interaction between
bacteria and the immune system in SLE.

Identifying and repurposing drug targets
Recent advances presented at the meeting
identified new drug targets and repurposed
therapies for use in SLE. Both Mariana
Kaplan (National Institute of Arthritis and
Musculoskeletal and Skin Diseases) and
Laurence Morel (University of Florida)
demonstrated how targeting immune

metabolism, specifically mitochondrial
respiration, could improve disease burden in
patients with SLE. Morel presented data for
both humans and mice with SLE, showing
that metformin, widely used to treat type
2 diabetes, reduced prednisone use and
decreased the number of flares in SLE15.
Metformin’s debated mechanisms of action
not only affect the AMPK–mTOR–STAT3
pathway, but also, potentially, the electron
transport chain, by inhibiting complex I.
As a result, metformin reduces oxidative
phosphorylation in CD4+ T cells isolated
from patients with lupus and decreases IFN-γ
production. This finding was recapitulated in
Sle1Sle2Sle3 mice, but effects varied in other
lupus mouse models, which is potentially
indicative of strain-specific mechanisms
involving mitochondrial respiration16.
Another repurposed drug, presented
by Kaplan, demonstrated the benefit of
targeting mitochondrial dysfunction to
reduce aberrant apoptosis that occurs in
SLE. Used in clinical trials for muscular
dystrophies and neuropathies, idebenone
acts as an antioxidant that bypasses complex
I activity and enhances ATP synthesis.
Without suppressing the immune system,
idebenone improved renal disease in
both the MRL/lpr and NZM2328 strains,
decreased mitochondrial ROS production
and neutrophil extracellular trap formation,
and attenuated vasculopathy17. Similar
findings were observed with the use of
Mito-Q, another mitochondrial antioxidant,
in MRL/lpr mice. These findings, along
with Morel’s, demonstrate the potential of
targeting immunometabolism in SLE.
The prospect of using anti-hypertensive
angiotensinogen-converting enzyme (ACE)
inhibitors to treat neuropsychiatric lupus
manifestations was presented by Betty
Diamond (Feinstein Institute). Building
upon increased brain parenchymal ACE
expression in lupus mice, Diamond
demonstrated that administration of ACE
inhibitors led to decreased microglial
activation, prevented dendritic loss by
increasing expression of the inhibitory
receptor LAIR-1 and improved cognition in
lupus mice18. Furthermore, in conjunction
with human evidence indicating that ACE
polymorphisms are associated with SLE,
these findings demonstrate that modulating
microglia by ACE inhibition is a beneficial
repurposed therapy for patients with
neuropsychiatric lupus.
Chaim Putterman (Azrieli Faculty
of Medicine) discussed the potential of
targeting CD6–ALCAM (activated leukocyte
cell adhesion molecule) interactions,
which are involved in the costimulation
and activation of T cells as well as the
trafficking of effector T cells into tissues.
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Fig. 3 | Using overlapping disease signatures in appropriate mouse models and subclusters of
patients with lupus for the development of targeted therapies. With advanced technology, it is
possible to select specific mouse models that recapitulate the molecular features found in subgroups
of patients with lupus. The insights and therapies resulting from studying these high-fidelity models
should be translated back to their matching patient subgroups, increasing the likelihood of improving
patient care.

Itolizumab is a monoclonal antibody
targeting CD6 that blocks CD6–ALCAM
interactions without depleting T cells.
In patients with SLE, urinary ALCAM
concentrations are elevated, particularly
in those with active lupus nephritis, and
are strongly correlated with SLE disease
activity index scores, glomerular filtration
rate and complement concentrations, and
thus could serve as a potential biomarker
for stratifying patients19. In MRL/lpr mice,
anti-CD6 treatment improved renal disease,
survival and extra-renal disease, such as
skin histopathology20. Subsequently, a phase
1b clinical trial with itolizumab has been
initiated for SLE and lupus nephritis, in
which urinary ALCAM and/or CD6 will
be followed to determine whether these
biomarkers can predict responsiveness to
itolizumab (NCT04128579).
Recent advances have not only identified
new drug targets but have also elucidated
potential adverse mechanisms contributing
to drug-induced lupus or autoimmunity,
as has been observed for tumor necrosis
factor (TNF) inhibitors. Tam Quach
(Feinstein Institute) highlighted the varying
mechanisms leading to autoantibody
production in different mouse models
lacking TNF, including extrafollicular
pathways, the induction of memory cells, and
aberrant germinal center formation. Quach
suggested that TNF may also influence
negative regulatory B cell functions, and
thus its deletion results in a change in the
threshold for the deletion of autoreactive
B cells, leading to disease acceleration and
increased mortality in permissive models.

Across human and mouse SLE data, there
are a number of emerging drug targets, new
or repurposed, that show promise and should
be further evaluated. Furthermore, additional
mouse model studies may reveal select stages
in lupus in which specific therapies would
have the greatest beneficial effect.

New technologies

In the past 10 years, innovative techniques
such as the CRISPR–Cas9 system and
single-cell RNA sequencing have broadly
improved the ability to test hypotheses
in disease models, shed new light on
established concepts in SLE, and highlight
the similarities and differences between
lupus mouse models and patients with SLE.
Eric Meffre (Yale University) investigated
the mechanisms contributing to defective
central B cell tolerance by using humanized
mice grafted with hematopoietic stem
cells21. In particular, the role of the tyrosine
phosphatase PTPN22, encoded by a risk
allele in SLE, was evaluated for its potential
contribution to the loss of tolerance.
Interestingly, blockade of PTPN22 in mice
humanized with SLE hematopoietic stem
cells corrected the loss of central tolerance
even when the risk allele was absent. Meffre
suggested that increased receptor editing
may account for the improvement.
In discerning the mechanisms
contributing to skin manifestations in
lupus, Mitra Maz (University of Michigan)
demonstrated differential type I IFN–
dependent immune responses in the skin of
lupus mice following UVB exposure, leading
to the subsequent recruitment of monocyte
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and macrophage populations. This work
complements previous reports that even
lupus keratinocytes from non-lesional
skin display a type I IFN signature22, thus
highlighting the complex interplay between
IFNs and both immune and stromal cells in
the pathogenesis of discoid lupus.
Another emerging avenue for research
includes the evaluation of altered homeostatic
pathways, such as circadian rhythms, in
lupus. Anne Davidson (Feinstein Institute)
presented on how the kidney-specific
circadian rhythm of renal homeostatic
functions, such as metabolism and blood
pressure regulation, are disrupted in nephritic
NZB×W/F1 lupus mice. Once remission is
induced, partial corrections in glycolysis,
vascular remodeling and regeneration and
reversal of the abnormal blood pressure
dipping pattern were observed in these
mice, causing their reversion to a younger,
healthier phenotype23. Davidson suggested
that renal circadian rhythms, including
urinary electrolyte excretion and blood
pressure, measured through ambulatory
blood pressure monitoring, could be tested
as disease biomarkers and may also help
dictate when specific therapeutics should
be administered to correspond with a target
organ’s internal processes.
Deepak Rao (Brigham and Women’s
Hospital) highlighted work from the
Accelerating Medicines Partnership network
characterizing the adaptive immune cells in
the kidneys of patients with lupus nephritis
and discussed the expansion of CD4+ T cells
among peripheral blood mononuclear cells
from patients with SLE. PD-1hiCXCR5–
peripheral helper T (TPH) cells were
identified and shown to mediate B cell help
in a manner dependent on the transcription
factor MAF24. With a similar transcriptomic
signature as that in TFH cells, emerging
evidence has identified the presence of TPH
cells in the pristane-induced lupus model. A
benefit of mouse models highlighted by Rao
is the ability to use the CRISPR–Cas9 and
Cre/loxP systems to elucidate the various
contributions similar and/or unique TFH and
TPH cell markers make to the cell’s function.
Further functional characterization of
TFH cells in SLE indicated the enhanced
role of STAT4 in the secretion of IL-21 and
IFN-γ. Jason Weinstein (Rutgers University)
demonstrated that mouse lupus TFH cells
develop a hyper-responsiveness to STAT4
activation over time that maintains cytokine
production, despite no observed increase
in the expression of either IFN receptors
or STAT4 itself25. Similar results were
observed in a cluster of circulating TFH-like
cells in patients with lupus, along with the
association of increased STAT4 activation
with disease severity.
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Erica Moore (Albert Einstein College
of Medicine) highlighted similarities
between the mouse and human T cell
receptor (TCR) repertoires in SLE. Using
CDR3 sequencing, enhanced sample
clonality demonstrated the directed
immune response present in patients
with SLE as compared to healthy controls.
Additional analysis of the TCR repertoires
revealed a skewed use of V genes in both
humans and mice and the potential to
use select TCR sequences as biomarkers
for diagnostic or prognostic purposes in
patients with SLE26. Furthermore, select
TCR sequences alongside T cell phenotyping
could be used to monitor specific organ
manifestations (Fig. 2), as highlighted
by an identified consensus sequence in
brain-infiltrating T cells in MRL/lpr mice
with neuropsychiatric manifestations27.
Paul Hoover (Brigham and Women’s
Hospital and Broad Institute) compared
human SLE signatures and lupus mouse
models using single-cell RNA sequencing.
The characterization of myeloid cells in
the kidneys of mice with lupus revealed
that the main populations were residential
macrophages, classical and non-classical
monocytes and circulating dendritic cells
in both Sle1Yaa and NZB/W models28.
Based on differentially expressed gene
profiles, a number of the myeloid signatures
present in humans, excluding the resident
macrophage cluster, were observed in the
two mouse lupus models, and some were
associated with nephritis. Furthermore,
Hoover showed preliminary data suggesting
that the monocyte subsets occupied similar
kidney compartments in both mouse and
human kidney tissue. Differences between
the lupus mouse strains were suggested to
mirror patient-specific phenotypes as well as
different aspects of disease.
Improved methodologies can more readily
elucidate mechanisms in greater detail and
with nuance and can identify mouse models
that may best match subsets of patients
with SLE. While no singular mouse model
recapitulates lupus disease in humans,
these recent studies highlight overlapping
mechanisms between patients with SLE
and mouse models and the possibility
of selectively using mouse models to
appropriately query facets of SLE pathogenesis
and develop new treatments (Fig. 3).

Concluding remarks

The meeting gathered early career and
established scientists and clinicians to
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debate and discuss the usefulness of lupus
mouse models. Through human and
mouse data comparisons as well as lengthy
discussions, the data presented showed
that lupus mouse models still perform an
irreplaceable function in modelling systemic
autoimmunity and elucidating facets of
disease pathogenesis. More specifically,
experimental manipulations in these
models have accelerated various avenues
of research, including identifying internal
triggers, via alterations in the microbiome;
target-organ-specific mechanisms;
and emerging drug targets, such as
immunometabolism. Recognizing the
heterogeneity of lupus manifestations and
likely disease mechanisms, the consensus
was to continue using lupus mouse models
but to do so in a purposeful and directed
manner, testing specific questions relevant
to the particular model. Furthermore,
technological advances will enhance our
ability to first use findings in particular
subsets of patients with SLE, which will
guide the selection of mouse models and
experiments in developing targeted therapies
for the clinic.
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